The Simple BioTech Podcast – Détails, épisodes et analyse

Today is a very special episode where I will be discussing Biotech and Blockchain. Now you might be asking yourself - how do blockchain and biotech have anything to do with each other? That's exactly what i thought as well when I first heard of VitaDao. But after my conversation today I'm convinced that this is a collision of industries that was absolutely necessary. Vitadao is taking the world of crypto, and the world of BioTech and smashing them together in an explosion of innovation. 

VitaDao is a completely decentralized autonomous organization... also know as a DAO... now there's a high likelihood that that sounds like a foreign language, and that a lot of you have never heard of a decentralized autonomous organization.. fear not, we go deep into exactly what that means in this episode.

VitaDao is allowing any investor to invest in the absolute cutting edge BioTech technologies... the type of technologies that have so much potential, but carry so much risk, that the typical institutional investor or VC will pass on.

This conversation blew me away... just wait until you hear what they're doing with BioTech IP and NFTs. I don't want to spoil too much but this is an episode you won't want to miss.

Podcast notes and transcript available here: https://simplebiotechpodcast.com/tyler-golato-vitadao

-James Ruhle, SimpleBioTechPodcast.com

Stay up to date with the latest episodes and BioTech updates by following me on instagram @SimpleBioTech

If you want to know which BioTech companies I'm currently excited about, connect with me on Angel List at Angel.co/jamesruhle

Locked in every bite of food we take is a universe of hidden potential. Potential to cure disease, help our sleep, and improve our mood just to name a few. The food we eat has a galaxy of molecules we call peptides, these peptides have limitless possibilities that get destroyed by the black hole we call our digestive system. These peptides have some truly miraculous healing qualities, but because of the extreme weakness in their bioavailability, to date humans have not been able to experience the benefits. 

Enter Nuritas - a company focusing on finding these miraculous peptides using AI technology, and extracting them from the food to become more bioavailable, essentially unlocking the full potential of the food that we eat. Dr. Nora khaldi is the brilliant woman behind Nuritas and today i had the pleasure of diving deep into the weeds with her while she explained just how this technology works, and what it means for human civilization going forward. So without further ado, Dr. Nora Khaldi.

Podcast notes and transcript available here: https://simplebiotechpodcast.com/nora-khaldi-nuritas

-James Ruhle, SimpleBioTechPodcast.com

Stay up to date with the latest episodes and BioTech updates by following me on instagram @SimpleBioTech

If you want to know which BioTech companies I'm currently excited about, connect with me on Angel List at Angel.co/jamesruhle

Andy Koff is the Founder of Atropos Therapeutics. A company with a new approach to tackling senescent cells, one fo the biggest hallmarks of aging.

Atropos Therapeutics uses a bio marker to identify when a cell starts transitioning from a quiescent cell into a senescent cell. Using this bio marker, Atropos aims to be able to prevent the cell from transitioning into a senescent cell, they've dubbed this type of technology a "senosuppressant"

For 25 years or so, starting with his post-graduate work at the Fred Hutchinson Cancer Center with Jim Roberts, and into his faculty position at Memorial Sloan Kettering Cancer Center, Andy has used a multitude of approaches, biochemical, genetic and cellular, to identify the proteins and the mechanisms that control how cells choose between duplicating themselves, known as proliferating, or remaining in a non-proliferating state.  This decision is incorrectly made in virtually all cancer cells, thus providing the framework to explain much about how drugs work in oncology.

About five years ago, Andy’s attention shifted to another decision…how cells maintain themselves in the non-proliferating state and what might be the consequences to not being able to do so. His work today has applications in both oncology and in aging and age-related diseases.

-James Ruhle, SimpleBioTechPodcast.com

Stay up to date with the latest episodes and BioTech updates by following me on instagram @SimpleBioTech

If you want to know which BioTech companies I'm currently excited about, connect with me on Angel List at Angel.co/jamesruhle

Mike West is a legend in the field of Gerontology, the study of aging. Back in the 90's, Mike's company Geron Corp, was the first company to not only successfully isolate embryonic stem cells, but to also isolate the telomerase gene, also known as the immortalizing gene. Gerons discoveries were so significant they prompted the former President of the United States to address the nation.

It was an absolute honor to speak with Mike West, who is currently the CEO of Age X Therapeutics. The conversation, initially planned for only 30 minutes, flew by as it turned into an hour and a half long, mind blowing conversation about pluripotent stem cells, telomerase, and the absolute sci fi levels of potential behind these technologies.

Arnold Schwarzenegger babies, glowing dogs, a 600 year human life span, and growing replacement organs in a petri dish are just a few of the topics we discussed on today's episode. Strap in, because this conversation is going to take you into orbit.

-James Ruhle, SimpleBioTechPodcast.com

Stay up to date with the latest episodes and BioTech updates by following me on instagram @SimpleBioTech

If you want to know which BioTech companies I'm currently excited about, connect with me on Angel List at Angel.co/jamesruhle

In this interview Graham Pawelec, a top academic in cancer research and immunotherapy, breaks down exactly how the immune system protects us, why it becomes less effect as we age, and how scientists are utilizing the immune system to cure cancer. Yes... to CURE cancer. If you're curious just how close we are to eliminating cancer, tune in to this exciting episode.

The timing of the podcast comes at a morbidly convenient time. Graham also explains exactly why the COVID-19 virus has been so detrimental to older people in particular, and why the immune systems of older people have such a hard time fighting new diseases.

In hindsight, after this interview, it seems pretty obvious how important the immune system is going to be in the bigger picture of truly eliminating aging. A stronger immune system means a stronger defense against life threatening disease. Less possibility of life threatening disease... means a longer life.

-James Ruhle, SimpleBioTechPodcast.com

Stay up to date with the latest episodes and BioTech updates by following me on instagram @SimpleBioTech

If you want to know which BioTech companies I'm currently excited about, connect with me on Angel List at Angel.co/jamesruhle

Today's episode is an interview with Tim Cash, Chief Science Officer of Senolytx Therapeutics, one of the six daughter companies of David Sinclair's Life BioSciences.

In this episode Tim helps me to understand exactly why senescent cells, and the damage they cause to the human body is such an important issue we, as humans, need to fix. If you're interested in learning why and how the human body ages, you're going to love this episode.

We go over the different methods and theories behind fixing senescent cells:
senolytics, senomorphics, and utilizing the immune system to get rid of them naturally, as well as touch on how Senolytx is navigating the regulatory hurdles by focusing on Fibrosis initially, as their main target, with the broader goal of targeting aging as a whole as they progress through clinical trials.

We also go into some of the promising results Senolytx is seeing with their therapies, and Tim enlightens me on some of the most exciting things happening in BioTech right now, and where he see's things in the next 5, 10, and 15 years.

-James Ruhle, SimpleBioTechPodcast.com

Stay up to date with the latest episodes and BioTech updates by following me on instagram @SimpleBioTech

If you want to know which BioTech companies I'm currently excited about, connect with me on Angel List at Angel.co/jamesruhle 

What if I were to tell you that each and every one of us has a universe inside of us that controls our mood, how we age, and even what we're allergic to. A universe inside of our guts filled with trillions of microorganisms that make up our gut microbiome that dictate our lives from the moment we're born.

Having a healthy gut microbiome from birth is a massive part of living a long, happy life. However, in recent years, because of changes to how we raise our children researchers have noticed that infants of today have less and less of these extremely important bacteria which can cause life long issues for babies that are born today.

This is a serious issue, on a global scale, and it's one that can't be ignored. My guest today is an absolute stud in the world of biotech, and is tackling this issue head on with Evolve Biosystems. In this interview I get educated on the different strains of probiotics, why they're so important, why the children born today have less of them and why that is such a problem, as well as some tips for adults that have nuked their guts with things like antibiotics.

My guest today... Chief Science Officer and Chairman of Evolve Biosystems, David Kyle.

Podcast notes and transcript available here: https://simplebiotechpodcast.com/david-kyle-evolve-biosystems

-James Ruhle, SimpleBioTechPodcast.com

Stay up to date with the latest episodes and BioTech updates by following me on instagram @SimpleBioTech

If you want to know which BioTech companies I'm currently excited about, connect with me on Angel List at Angel.co/jamesruhle

Imagine if you could turn the characteristics of a cell on and off… or up and down like a volume trigger… constantly tuning things until everything is working just right. It might sound impossible, but that’s exactly what Obsidian therapeutics is working on.

I’ll admit, it was tough for me to wrap my mind around this one at first, but my guest today did a fantastic job of explaining things. So without further ado, chief development officer of Obsidian therapeutics, Catherine Stehman-Breen.

Podcast notes and transcript available here: https://simplebiotechpodcast.com/catherine-stehman-breen-obsidian-therapeutics

-James Ruhle, SimpleBioTechPodcast.com

Stay up to date with the latest episodes and BioTech updates by following me on instagram @SimpleBioTech

If you want to know which BioTech companies I'm currently excited about, connect with me on Angel List at Angel.co/jamesruhle

Everyone's dealt with anxiety and depression to some extent, at some point in their lives. It can be debilitating and can cause feelings of hopelessness and helplessness.

My guest, Shawn Singh wants to change that. Him and his company, Vistagen Therapeutics are taking on anxiety and depression with their unique bio technology that aims to leave the nasty side effects of anxiety and depression meds behind

Vistagen Therapeutics is a publicly traded company on the Nasdaq stock exchange under the ticket VTGN.

If you are someone who's dealt with either anxiety or depression this episode is for you.

Podcast notes and transcript available here: https://simplebiotechpodcast.com/shawn-singh-vistagen-therapeutics

-James Ruhle, SimpleBioTechPodcast.com

Stay up to date with the latest episodes and BioTech updates by following me on instagram @SimpleBioTech

If you want to know which BioTech companies I'm currently excited about, connect with me on Angel List at Angel.co/jamesruhle

Imagine being blind and you can see again. Imagine being paralyzed and you can move again. Imagine how amazing it would feel to be cured of cancer. Life changing would be an understatement. My guest today is the CEO of a company that is leading the way in cell therapy, a technology that can do just that; cure the blind, give movement to the paralyzed, and cure cancer. Brian Culley is the CEO of Lineage Cell Therapeutics, a publicly traded company on the NYSE. Stock ticker: LCTX

Lineage Cell Therapeutics has had some extremely promising results by using the power of Pluripotent stem cells. This was a fascinating and exciting conversation and Brian does a great job of explaining complicated subjects so the average person can understand.

If you're curious about the almost magic like power of Pluripotent stem cells, and all that they can do, than this is a must listen.

Podcast notes and transcript available here: https://simplebiotechpodcast.com/brian-culley-lineage-cell-therapeutics

-James Ruhle, SimpleBioTechPodcast.com

Stay up to date with the latest episodes and BioTech updates by following me on instagram @SimpleBioTech

If you want to know which BioTech companies I'm currently excited about, connect with me on Angel List at Angel.co/jamesruhle